Navigation Links
Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia

ine.com/">http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward- looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general as well as, risk and uncertainties associated with the Company's indiplon program and planned commercialization activities, including but not limited to; risk that we will be unable to resubmit the indiplon capsule NDA in a timely manner or at all; risk that regulatory authorities may refuse to accept the filing of our resubmission of the indiplon capsule NDA; risk that regulatory authorities may find our resubmission of the indiplon capsule NDA incomplete or insufficient or otherwise unapprovable or that approval may be delayed; risk that following approval of indiplon capsules, commercialization may be delayed for any of a number of reasons including market conditions and product supply; risk that we will not be able to independently commercialize indiplon capsules or find a marketing partner on reasonable terms or at all; risk that the indiplon capsule labeling granted by regulatory authorities may limit the commercial success of indiplon capsules; and risk relating to market acceptance of indiplon capsules following marketing approval; in addition to the other risks described in the Company's report on Form 10-K for the year ended December 31, 2006 and Form 10-Q for the quarter ended March 31, 2007. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

CONTACT: Investors, Elizabeth Foster of Neurocrine Biosciences,+1-858-617-7600; or Media, Liz Frank of WeissComm Partners, +1-212-301-7216

Web site: http://www.neurocrine.com/


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in New York on ... . Dr. Helen Torley , President and Chief ... presentation will be webcast through the "Investors" section of Halozyme,s ... be made available for 90 days following the event. To ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Feb. 23, 2012  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX® in ... today announced that its partner Auxilium Pharmaceuticals, Inc. ... Pharmaceuticals Ltd. (Actelion) for the long-term development, supply ...
... Feb. 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2011 ... virus (HCV) development pipeline. Operational ...
Cached Medicine Technology:BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 2BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 3BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. ... Award from The American Association of Nurse ... of nurse practitioners. The Distinguished Preceptorship Award recognizes ... a significant contribution toward increasing the awareness and ... Practitioners (AANP) is the largest full-service national professional ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Vultures have developed highly ... ingest when eating dead animals, researchers report. The ... on the faces and in the guts of 50 ... On average, the faces of the vultures had more ... in their guts, the study found. The findings ...
(Date:11/26/2014)... Exposure to peanut protein in household dust may increase ... skin condition eczema, a new study reveals. About ... are allergic to peanuts. And severe eczema in infants ... the researchers noted. The new study included 359 ... examined the amount of peanut protein the children were ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Parents need to take an ... an expert warns. Parents must make sure sports-playing ... Dr. David Dodick, chair of the American Migraine Foundation ... College of Medicine in Scottsdale, Ariz. in an American ... Any coach involved with teens sports needs to ...
(Date:11/24/2014)... Los Angeles, CA (PRWEB) November 24, 2014 ... to bringing its readers reviews of affordable skin care ... , the casual blog offers readers a wide variety ... the market as well as organic skincare alternatives. , ... Healthy Skin Care Journal’s main content includes thoroughly researched ...
Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2
... a bacteria resistant to certain antibiotics. This bacteria occurs ... especially in hospitals and nursing homes and is known ... the Netherlands, Sweden, and Norway, where MRSA has been ... facing an increase in incidence with the rates starting ...
... – 'In Zambia, people in the tourist resort city of ... dead chickens at the owners backyards'. // ,Simon ... confirmed evidences were found after thorough investigation of the outbreak'. ... not been cleared yet but residents who cooked and ate ...
... future for those suffering with the deadly disease of Hepatitis C ... that he would speak with the government for the introduction of ... these diseases while administering blood and blood products. ,This ... , These people suffer from the problem of not ...
... Yale university researchers it was found that forced out of work ... rate of heart attacks //. They analyzed about 4,301 people between ... the study were published in the Occupational and Environmental Medicine journal. ... in about 10 years time period as they were forced out ...
... After the vocal demonstrations in hospitals against reservation policy ... face//. This time it is by the staff ... The bone of contention is the incident wherein some ... administration now is taking steps to check overcrowding of ...
... the Wake Forest University School of Medicine and colleagues ... difficult medical procedures //about the dizzy feel of nausea ... strongly affect how they respond to adversity – both ... Ph.D. ‘Being prepared for difficulty can benefit people greatly.’ ...
Cached Medicine News:Health News:Super-bug MRSA Getting Fitter And Out of Control 2Health News:Precautious Measure Help Tolerate Nausea In Patients 2Health News:Precautious Measure Help Tolerate Nausea In Patients 3
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Medicine Products: